Cathy Friedman is a business executive with nearly 40 years of experience across finance, technology, and healthcare. Cathy is an Executive Venture Partner at GV, where she is a senior member of the investing team and advises the life sciences portfolio.
Cathy has spent 15 years on the boards of leading public and private life sciences and technology companies. Recently, in addition to her role as Chair of the Board at Grail (acquired by Illumina), she has been an independent director at Vividion Therapeutics (acquired by Bayer), Lyell Immunopharma, Seer, Altaba (formerly Yahoo!), Radius Health, and Revolution Healthcare Acquisition Corp.
Earlier in her career, Cathy spent nearly 24 years with Morgan Stanley. She held several executive positions, including Managing Director, Head of West Coast Healthcare, and co-head of Morgan Stanley's biotechnology practice.
Cathy holds a B.A. in economics from Harvard University and an M.B.A from The University of Virginia's Darden School of Business. She is a foundation trustee for the University of California San Francisco and the University of Virginia's Darden School of Business. Cathy resides in the Bay Area with her husband and enjoys spending time with her six children.